{"preliminary_commentary":{"by_channel":{"youtube":3,"x_thread":3,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT00632853\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"CALGB-30610","nct_id":"NCT00632853","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=calgb-30610-nct00632853. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Radiotherapy (every day, Monday-Friday, for a total of 3 weeks) XRT: 45 Gy BID (1.5 Gy/fx) starting on day 1 of Cycle 1 or 2, every day, for 3 weeks\n\nChemotherapy (every 21 days for 4 cycles, for a total of 12 weeks):\n\n* Cisplatin 80 mg/m2 IV on day 1 OR Carboplatin AUC 5 IV day 1, every 21 days\n* Etoposide 100 mg/m2 IV Register/ on days 1, 2, and 3, every 21 days","label":"Arm A - Standard Radiotherapy + Chemotherapy","type":"ACTIVE_COMPARATOR"},{"description":"Radiotherapy (every day, Monday-Friday, for a total of 7 weeks) XRT: 70 Gy QD (2.0 Gy/fx), starting on day 1 of Cycle 1 or 2, every day, for 7 weeks\n\nChemotherapy (every 21 days for 4 cycles, for a total of 12 weeks):\n\n* Cisplatin 80 mg/m2 IV on day 1 OR Carboplatin AUC 5 IV day 1, every 21 days\n* Etoposide 100 mg/m2 IV on days 1, 2, and 3, every 21 days","label":"Arm B - High Dose Radiotherapy + Chemotherapy","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2026-04-15","type":"ACTUAL"},"conditions":["Lung Cancer"],"enrollment":{"count":731,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Standard Radiation Dose Therapy","otherNames":[],"type":"RADIATION"},{"name":"cisplatin","otherNames":[],"type":"DRUG"},{"name":"etoposide","otherNames":[],"type":"DRUG"},{"name":"High Radiation Dose Therapy","otherNames":[],"type":"RADIATION"},{"name":"carboplatin","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-10","lead_sponsor":"Alliance for Clinical Trials in Oncology","official_title":"Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2022-03-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival Time","timeFrame":"11.25 years"}],"references":[{"citation":"Farris MK, Mix MD, Wang X, Jaszewski B, Foster N, Masters GA, Laurie F, Smith K, Razavian NB, Alden RS, Komaki R, Stinchcombe TE, Bradley JD, Vokes EE, Bogart J. Prognostic Factors in Limited-Stage Small Cell Lung Cancer: A Secondary Analysis of CALGB 30610-RTOG 0538. JAMA Netw Open. 2024 Oct 1;7(10):e2440673. doi: 10.1001/jamanetworkopen.2024.40673.","pmid":"39446327","type":"DERIVED"},{"citation":"Bogart J, Wang X, Masters G, Gao J, Komaki R, Gaspar LE, Heymach J, Bonner J, Kuzma C, Waqar S, Petty W, Stinchcombe TE, Bradley JD, Vokes E. High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538. J Clin Oncol. 2023 May 1;41(13):2394-2402. doi: 10.1200/JCO.22.01359. Epub 2023 Jan 9.","pmid":"36623230","type":"DERIVED"}],"start_date":{"date":"2008-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide","url":"https://clinicaltrials.gov/study/NCT00632853"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/calgb-30610-nct00632853"}